Related Experiment Video
Updated: Mar 25, 2026
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Evaluation of a breast cancer nomogram to predict ipsilateral breast relapse after breast-conserving therapy
Isabelle Kindts1, Annouschka Laenen2, Stephanie Peeters1
1KU Leuven - University of Leuven, Department of Oncology, Belgium; University Hospitals Leuven, Department of Radiation Oncology, Belgium.
Background And Purpose:
A nomogram to predict for the 10-year ipsilateral breast relapse (IBR) after breast-conserving therapy (BCT) for breast cancer (BC) was developed based on the 'boost-no-boost'-trial with a concordance probability estimate (CPE) of 0.68. The aim of our study was to validate that algorithm.
Material And Methods:
We retrospectively identified 1787 BC cases, treated with BCT and radiotherapy at the University Hospitals Leuven from 2000 to 2007, without missing data of the nomogram variables. Clinicopathologic factors were assessed. Validity of the prediction model was tested in terms of discrimination and calibration.
Results:
Median follow-up time was 10.75years. The validation cohort differed with respect to the administration of a radiation boost, chemo- or hormonal therapy, age, tumour diameter or grade, ductal carcinoma in situ and hormone receptor positivity. On multivariable analysis, the omission of the boost was a significant prognosticator of IBR (p<0.01). The 10-year IBR-rate was 1.4%. The nomogram demonstrated suboptimal discrimination (CPE 0.54) and calibration, with an overestimation of the IBR-risk in general.
Conclusions:
The predictive model for IBR in BC is imperfect in this more recent study population.
